ZLAB News and Press, Zai Lab Limited From 04/11/23

SHANGHAI and CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data including a translational and biomarker data analysis from its internal oncology discovery program ZL-1211 at the upcoming 2023 American Association for Cancer Resear...

2023-03-26 07:45:00 ET There's a good chance that Zai Lab 's (NASDAQ: ZLAB) stock will make a journey into the stratosphere in the next few years, and that means growth-hungry investors should consider loading up on its shares, and soon. Whereas other mid-cap biotechs of roughly...

2023-03-23 07:54:57 ET Royalty Pharma ( NASDAQ: RPRX ) has acquired PureTech Health’s ( NASDAQ: PRTC ) royalty interest in KarXT, the lead investigational product of Karuna Therapeutics ( NASDAQ: KRTX ), for up to $500M, according to a Thursday press rel...

2023-03-21 16:01:16 ET Karuna Therapeutics ( NASDAQ: KRTX ) dropped for the second straight session on Tuesday to reach a seven-month low, while Wall Street brushed off safety results in a Phase 3 readout for its schizophrenia candidate KarXT, co-developed with Zai Lab Limited (...

2023-03-21 06:49:26 ET Following a ~5% drop in the prior session despite a trial win, Karuna Therapeutics ( NASDAQ: KRTX ) shares continued to tumble in the pre-market trading Tuesday after announcing the start of a $400.0M offering of its common stock. The underwritten pu...

Third positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001) KarXT was generally well tolerated, with a side effect profile substantially consistent with previous trials of ...

2023-03-13 08:00:00 ET Summary Zai Lab is set to reach several product milestones this year, as at least eight new products are on track for approval by the end of 2025. With $1 billion in cash reserves, the company has sufficient resources to keep exploring new drugs. The vas...

2023-03-06 16:54:50 ET Summary Zai lab's diversified pipeline, strong partnerships, and proven track record of successful drug development make it an attractive investment opportunity in the biotech industry. The recent acceptance of the New Drug Application for sulbactam-durlobac...

Zai Lab Limited (ZLAB) Q4 2022 Earnings Conference Call March 02, 2023 08:00 AM ET Company Participants Billy Cho - Chief Financial Officer Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - Chief Operating Officer Rafael Amado - President...

The following slide deck was published by Zai Lab Limited in conjunction with their 2022 Q4 earnings call. For further details see: Zai Lab Limited 2022 Q4 - Results - Earnings Call Presentation